Protalix BioTherapeutics vs Recursion Pharmaceuticals
PLX and RXRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PLX and RXRX compare
Recursion Pharmaceuticals is the larger company, worth 6.9 times as much as Protalix BioTherapeutics ($1.7B against $246M).
Recursion Pharmaceuticals grew revenue faster over the last twelve months (56.2% versus 37.0% for Protalix BioTherapeutics).
Protalix BioTherapeutics keeps more of each dollar of sales as profit, with a net margin of 24.3% compared with −697% at Recursion Pharmaceuticals.
Protalix BioTherapeutics scores higher on the StockData Score (16 against 8 for Recursion Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PLX | RXRX |
|---|---|---|
| Size and price | ||
| Market cap | $246M | $1.7B |
| Share price | $3.05 | $3.19 |
| Change, 1 year | 42.5% | −31.5% |
| Change, 5 years | 211% | −83.9% |
| Beta (5Y) | 0.87 | 2.65 |
| Employees | 226 | 50 |
| StockData Score | ||
| Total score | 16 (better) | 8 |
| Valuation score | 4 (better) | 1 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 12.2× | – |
| P/S | 2.9× (better) | 25.0× |
| P/B | 3.1× | 1.9× (better) |
| EV/EBITDA | 8.9× | – |
| P/FCF | 16.3× | – |
| FCF yield | 6.1% (better) | −18.3% |
| Fair value | $6.09 | $3.14 |
| Margin of safety | 49.9% (better) | −1.5% |
| Growth | ||
| Revenue growth (TTM) | 37.0% | 56.2% (better) |
| Revenue growth, 5Y average | −3.5% | 79.9% (better) |
| Net income growth (TTM) | 281% | – |
| EPS growth (TTM) | 525% | – |
| Profitability | ||
| Gross margin | 71.2% (better) | 29.2% |
| Operating margin | 29.8% (better) | −725% |
| Net margin | 24.3% (better) | −697% |
| FCF margin | 17.8% (better) | −458% |
| Return on equity | 30.8% (better) | −48.7% |
| Return on invested capital | 41.0% (better) | −102% |
| Financial health | ||
| Debt / equity | 0.00 | 0.01 (better) |
| Interest coverage | – | −541.6× |
| Current ratio | 3.27 | 5.01 (better) |
| Altman Z-score | 6.03 (better) | −0.36 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | −12.8% |
| Shareholder yield | 0.00% (better) | −12.8% |
| Ownership | ||
| Held by institutions | 17.9% | 67.6% |
| Held by insiders | 3.8% | 5.6% |
| Insider net buying, 12 months | $101K (better) | −$7.4M |
| Short interest, % of float | 4.5% | 28.2% |
Go deeper
- PLX stock overview
- PLX income statement
- PLX valuation and score
- RXRX stock overview
- RXRX income statement
- RXRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.